| Animal models for liver disease–a practical approach for translational research YA Nevzorova, Z Boyer-Diaz, FJ Cubero, J Gracia-Sancho Journal of hepatology 73 (2), 423-440, 2020 | 173 | 2020 |
| Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease Z Boyer-Diaz, P Aristu-Zabalza, M Andrés-Rozas, C Robert, ... Journal of hepatology 74 (5), 1188-1199, 2021 | 91 | 2021 |
| Emricasan ameliorates portal hypertension and liver fibrosis in cirrhotic rats through a hepatocyte‐mediated paracrine mechanism J Gracia‐Sancho, N Manicardi, M Ortega‐Ribera, R Maeso‐Díaz, ... Hepatology communications 3 (7), 987-1000, 2019 | 47 | 2019 |
| GNIP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscle M Montori-Grau, R Pedreira-Casahuga, Z Boyer-Díaz, I Lassot, ... Metabolism 83, 177-187, 2018 | 23 | 2018 |
| Oxidative stress in chronic liver disease and portal hypertension: potential of DHA as nutraceutical Z Boyer-Diaz, P Morata, P Aristu-Zabalza, A Gibert-Ramos, J Bosch, ... Nutrients 12 (9), 2627, 2020 | 19 | 2020 |
| New rat model of advanced NASH mimicking pathophysiological features and transcriptomic signature of the human disease R Maeso-Díaz, Z Boyer-Diaz, JJ Lozano, M Ortega-Ribera, C Peralta, ... Cells 8 (9), 1062, 2019 | 19 | 2019 |
| A nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease Z Boyer-Diaz, JC Domingo, E De Gregorio, N Manicardi, P Aristu-Zabalza, ... Nutrients 11 (10), 2358, 2019 | 17 | 2019 |
| The pan-ppar agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease P Aristu, Z Boyer-Diaz, P Broqua, JL Junien, G Wettstein, J Bosch, ... Hepatology 70, 44A-45A, 2019 | 4 | 2019 |
| STATINS IMPROVE LIVER FUNCTION AND MINIMIZE THE DEGREE OF LIVER DAMAGE BY MODULATING CELL DEATH AH Gutierrez, Z Kang, Z Boyer-Diaz, A Lamas Paz, J Vaquero, R Banares, ... HEPATOLOGY 78, S1133-S1133, 2023 | | 2023 |
| INHIBITION OF THE LYSOPHOSPHATIDIC ACID PATHWAY IMPROVES HEPATIC FIBROSIS AND PORTAL HYPERTENSION IN EXPERIMENTAL ADVANCED CHRONIC LIVER DISEASE P Aristu, Z Boyer-Diaz, A Zagorska, M Sharma, M Andres-Rozas, G Budas, ... HEPATOLOGY 78, S1201-S1202, 2023 | | 2023 |
| GTX-011 improves fibrosis and hepatic stellate cells phenotype in human precision cut liver slices M Andres-Rozas, Z Boyer-Diaz, E Ruiz-Canovas, S Guixe-Muntet, ... Journal of Hepatology 78, S791, 2023 | | 2023 |
| GTX-011 improves portal hypertension, liver fibrosis and endothelial dysfunction in a rat model of non-alcoholic steatohepatitis M Andrés-Rozas, Z Boyer-Diaz, E Ruiz-Cánovas, P Aristu-Zabalza, ... | | 2021 |
| HEPATIC FATTY ACID PROFILE IN CHRONIC LIVER DISEASE: MECHANISM OF INJURY AND NOVEL THERAPEUTIC TARGET Z Boyer-Diaz, J Carles Domingo, B Cordobilla, P Aristu, P Morata, ... HEPATOLOGY 70, 1253A-1254A, 2019 | | 2019 |
| Introducing a new pre-clinical model of advanced NASH that mimics the main pathophysiologic characteristics and transcriptomic signature of the human disease R Maeso Diaz, Z Boyer-Diaz, C Peralta, J Bosch, J Gracia-Sancho JOURNAL OF HEPATOLOGY 70, E538-E539, 2019 | | 2019 |
| A nutraceutical supplement rich in docosahexaenoic acid improves portal hypertension in a preclinical model of chronic liver disease Z Boyer-Diaz, N Manicardi, P Aristu, L Abad, A Fernández-Iglesias, ... Journal of Hepatology 70, E435-E436, 2019 | | 2019 |
| Molecular Mechanisms Underlying the Beneficial Effects of Emricasan in Portal Hypertension and Chronic Liver Disease: Relevance of the Hepato-Sinusoidal Cross-Talk. J Gracia-Sancho, N Manicardi, M Ortega-Ribera, A Fernandez-Iglesias, ... HEPATOLOGY 68, 773A-774A, 2018 | | 2018 |
| GNIP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscle A Gómez-Foix, J Jiménez-Chillarón, S Desagher, M Vázquez-Carrera, ... | | 2018 |
